ASX - By Stock
|
TLX |
Re:
Ann: Telix Successfully Prices A$650M Convertible Bonds
|
|
KCRCH
|
69 |
23K |
5 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
69
|
23K
|
5
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix Announces A$600 Million Convertible Bonds Offering
|
|
KCRCH
|
41 |
13K |
6 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
41
|
13K
|
6
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix Q2 2024 Revenue/Business Highlights, Guidance Upgrade
|
|
KCRCH
|
51 |
20K |
3 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
51
|
20K
|
3
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
KCRCH
|
1.1K |
569K |
2 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
1.1K
|
569K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix Elects to Withdraw from Proposed U.S. Listing
|
|
KCRCH
|
116 |
45K |
5 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
116
|
45K
|
5
|
|
ASX - By Stock
|
TLX |
Re:
News: TLX Telix Pharmaceuticals Aims Up To $4.17 Bln Valuation In US IPO
|
|
KCRCH
|
112 |
45K |
20 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
112
|
45K
|
20
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Q3 2023 Business Update to Accompany Quarterly Results
|
|
KCRCH
|
138 |
53K |
3 |
03/11/23 |
03/11/23 |
ASX - By Stock
|
138
|
53K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
TLX
|
|
KCRCH
|
89 |
35K |
4 |
17/10/23 |
17/10/23 |
ASX - By Stock
|
89
|
35K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
Ann: First Patient Dosed in Phase 3 Illuccix China Study
|
|
KCRCH
|
13 |
4.0K |
4 |
11/08/23 |
11/08/23 |
ASX - By Stock
|
13
|
4.0K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
I'm Curious .. Why are You Selling Telix
|
|
KCRCH
|
8 |
4.0K |
4 |
07/07/23 |
07/07/23 |
ASX - By Stock
|
8
|
4.0K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
Telix in China
|
|
KCRCH
|
64 |
25K |
0 |
20/05/23 |
20/05/23 |
ASX - By Stock
|
64
|
25K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
KCRCH
|
1.5K |
596K |
5 |
19/05/23 |
19/05/23 |
ASX - By Stock
|
1.5K
|
596K
|
5
|
|
ASX - By Stock
|
TLX |
Re:
Competition
|
|
KCRCH
|
254 |
116K |
0 |
06/05/23 |
06/05/23 |
ASX - By Stock
|
254
|
116K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix-Grand Pharma Investor Webcast Notification
|
|
KCRCH
|
38 |
13K |
5 |
22/04/23 |
22/04/23 |
ASX - By Stock
|
38
|
13K
|
5
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
KCRCH
|
1.1K |
569K |
0 |
19/04/23 |
19/04/23 |
ASX - By Stock
|
1.1K
|
569K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Australian TGA Approves Illuccix for Prostate Cancer Imaging
|
|
KCRCH
|
31 |
13K |
1 |
03/04/23 |
03/04/23 |
ASX - By Stock
|
31
|
13K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Australian TGA Approves Illuccix for Prostate Cancer Imaging
|
|
KCRCH
|
31 |
13K |
4 |
02/04/23 |
02/04/23 |
ASX - By Stock
|
31
|
13K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Chinese NMPA approves Phase III study of TLX591-CDx
|
|
KCRCH
|
10 |
3.3K |
2 |
17/10/22 |
17/10/22 |
ASX - By Stock
|
10
|
3.3K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix 1H 2022 Financial Results Investor Call Notification
|
|
KCRCH
|
3 |
1.7K |
1 |
18/08/22 |
18/08/22 |
ASX - By Stock
|
3
|
1.7K
|
1
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Lantheus 2022 Q2 insights and declaration of war addressed to Telix by President & CEO Mary Anne Heino
|
|
KCRCH
|
52 |
21K |
7 |
05/08/22 |
05/08/22 |
ASX - By Stock
|
52
|
21K
|
7
|
|
ASX - By Stock
|
ADO |
Re:
Ann: TGA Registration Update
|
|
KCRCH
|
2.4K |
734K |
0 |
13/01/22 |
13/01/22 |
ASX - By Stock
|
2.4K
|
734K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Hoping for $10 today?
|
|
KCRCH
|
43 |
18K |
0 |
31/12/21 |
31/12/21 |
ASX - By Stock
|
43
|
18K
|
0
|
|
ASX - By Stock
|
TLX Biotech |
Re:
TLX FDA Approval Pending Rocketship.
|
|
KCRCH
|
70 |
48K |
0 |
20/12/21 |
20/12/21 |
ASX - By Stock
|
70
|
48K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: FDA Approves Telix Prostate Cancer Imaging Product Illuccix
|
|
KCRCH
|
42 |
16K |
9 |
20/12/21 |
20/12/21 |
ASX - By Stock
|
42
|
16K
|
9
|
|
ASX - By Stock
|
TLX |
Re:
ATH
|
|
KCRCH
|
5 |
2.8K |
5 |
10/12/21 |
10/12/21 |
ASX - By Stock
|
5
|
2.8K
|
5
|
|
ASX - By Stock
|
TLX |
ATH
|
|
KCRCH
|
5 |
2.8K |
9 |
10/12/21 |
10/12/21 |
ASX - By Stock
|
5
|
2.8K
|
9
|
|
ASX - By Stock
|
TLX Biotech |
Re:
TLX FDA Approval Pending Rocketship.
|
|
KCRCH
|
70 |
48K |
1 |
15/11/21 |
15/11/21 |
ASX - By Stock
|
70
|
48K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Australian TGA Approves Illuccix for Prostate Cancer Imaging
|
|
KCRCH
|
31 |
13K |
8 |
02/11/21 |
02/11/21 |
ASX - By Stock
|
31
|
13K
|
8
|
|
ASX - By Stock
|
SP1 |
Re:
Confirmation Bias
|
|
KCRCH
|
148 |
39K |
14 |
16/10/21 |
16/10/21 |
ASX - By Stock
|
148
|
39K
|
14
|
|
ASX - By Stock
|
TLX |
Re:
Ann: FDA Extends New Drug Application Review Period for Illuccix
|
|
KCRCH
|
37 |
21K |
1 |
23/09/21 |
23/09/21 |
ASX - By Stock
|
37
|
21K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Ann: NCCN Guidelines updated to include PSMA-PET Imaging
|
|
KCRCH
|
12 |
5.7K |
9 |
21/09/21 |
21/09/21 |
ASX - By Stock
|
12
|
5.7K
|
9
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
KCRCH
|
48 |
21K |
4 |
20/09/21 |
20/09/21 |
ASX - By Stock
|
48
|
21K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
KCRCH
|
48 |
21K |
1 |
19/09/21 |
19/09/21 |
ASX - By Stock
|
48
|
21K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Is a $2,131,889,198.56 market cap justified
|
|
KCRCH
|
48 |
21K |
0 |
19/09/21 |
19/09/21 |
ASX - By Stock
|
48
|
21K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix Supporting Amgen PSMA-Targeting Therapy Trial
|
|
KCRCH
|
9 |
4.4K |
1 |
17/09/21 |
17/09/21 |
ASX - By Stock
|
9
|
4.4K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix and Radius sign Distribution Agreement for Italy
|
|
KCRCH
|
6 |
2.6K |
2 |
13/09/21 |
13/09/21 |
ASX - By Stock
|
6
|
2.6K
|
2
|
|
ASX - By Stock
|
TLX Biotech |
Re:
TLX FDA Approval Pending Rocketship.
|
|
KCRCH
|
70 |
48K |
11 |
13/09/21 |
13/09/21 |
ASX - By Stock
|
70
|
48K
|
11
|
|
ASX - By Stock
|
SP1 |
Re:
Class Action against ASX - who's in?
|
|
KCRCH
|
58 |
18K |
7 |
01/09/21 |
01/09/21 |
ASX - By Stock
|
58
|
18K
|
7
|
|
ASX - By Stock
|
BET |
Re:
Ann: TAH:Strategic Review conclusion and intention to demerge L&K
|
|
KCRCH
|
43 |
13K |
1 |
05/07/21 |
05/07/21 |
ASX - By Stock
|
43
|
13K
|
1
|
|
ASX - By Stock
|
BET |
Re:
Ann: TAH:Strategic Review conclusion and intention to demerge L&K
|
|
KCRCH
|
43 |
13K |
6 |
05/07/21 |
05/07/21 |
ASX - By Stock
|
43
|
13K
|
6
|
|
ASX - By Stock
|
TLX |
Re:
Ann: TLX101 for Glioblastoma Therapy - Clinical Trial Update
|
|
KCRCH
|
30 |
14K |
8 |
21/06/21 |
21/06/21 |
ASX - By Stock
|
30
|
14K
|
8
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Update on FDA New Drug Application Review for Illuccix
|
|
KCRCH
|
17 |
8.0K |
1 |
17/06/21 |
17/06/21 |
ASX - By Stock
|
17
|
8.0K
|
1
|
|
ASX - By Stock
|
SP1 |
Re:
ISX vs ASX
|
|
KCRCH
|
1.8K |
761K |
22 |
15/05/21 |
15/05/21 |
ASX - By Stock
|
1.8K
|
761K
|
22
|
|
ASX - By Stock
|
HCH |
Re:
Ann: Cortadera Drilling Update - More Copper and More Gold
|
|
KCRCH
|
80 |
22K |
11 |
16/04/21 |
16/04/21 |
ASX - By Stock
|
80
|
22K
|
11
|
|
ASX - By Stock
|
SP1 |
Re:
Round 2 ISX vs ASX
|
|
KCRCH
|
1.9K |
661K |
3 |
13/04/21 |
13/04/21 |
ASX - By Stock
|
1.9K
|
661K
|
3
|
|
ASX - By Stock
|
HCH |
Re:
Ann: Outstanding 813m Cu-Au Intercept at Cortadera
|
|
KCRCH
|
131 |
34K |
1 |
18/03/21 |
18/03/21 |
ASX - By Stock
|
131
|
34K
|
1
|
|
ASX - By Stock
|
ZIP |
Re:
Z1P partner Amazon Australia Posts 1.12 billion in sales
|
|
KCRCH
|
27 |
14K |
3 |
15/02/21 |
15/02/21 |
ASX - By Stock
|
27
|
14K
|
3
|
|
ASX - By Stock
|
SP1 |
Re:
Flykk Money
|
|
KCRCH
|
913 |
278K |
14 |
31/01/21 |
31/01/21 |
ASX - By Stock
|
913
|
278K
|
14
|
|
ASX - By Stock
|
BET |
Re:
Pricing BET
|
|
KCRCH
|
392 |
116K |
1 |
22/01/21 |
22/01/21 |
ASX - By Stock
|
392
|
116K
|
1
|
|
ASX - By Stock
|
BET |
Re:
Ann: BetMakers completes oversubscribed Share Purchase Plan
|
|
KCRCH
|
51 |
14K |
3 |
21/01/21 |
21/01/21 |
ASX - By Stock
|
51
|
14K
|
3
|
|